☆ 4.5 Article

Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study

RADIATION ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

Sorafenib Plus Hepatic ArterialInfusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TriaL

Kanglian Zheng et al.

Summary: This study compared the efficacy and safety of sorafenib plus 3cir-OFF hepatic arterial infusion chemotherapy (HAIC) with sorafenib alone for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (PVTT). The results showed that sorafenib plus HAIC achieved better overall survival (OS) and longer progression-free survival (PFS) compared to sorafenib alone, but also had more adverse events.

RADIOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis

Jeong Il Yu et al.

Summary: The combination of lenvatinib and liver-directed radiotherapy (LRT) is relatively safe and effective in increasing intrahepatic tumor response and improving progression-free survival (PFS) and intrahepatic progression-free survival (IHPFS) in patients with hepatocellular carcinoma (HCC) and macroscopic tumor thrombosis.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review

Zi-Wen Tao et al.

Hepatobiliary & Pancreatic Diseases International (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors

Norikazu Une et al.

Summary: The study analyzed the effects of lenvatinib and sorafenib on tumor vasculature in a mouse model of hepatocellular carcinoma and found that lenvatinib induced vascular normalization earlier and more effectively than sorafenib, increasing tumor radiosensitivity and enhancing the effect of combination therapy with lenvatinib and radiation against HCC.

MEDICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Impact of Local Liver Irradiation Concurrent Versus Sequential with Lenvatinib on Pharmacokinetics and Biodistribution

Tung-Hu Tsai et al.

Summary: The study found that the impact of lenvatinib combined with radiotherapy on liver concentration was more significant in the sequential treatment plan compared to the concurrent treatment plan. Additionally, the biodistribution of lenvatinib was significantly reduced in the concurrent treatment group.

CANCERS (2021)

添加到收藏夹

Article Oncology

Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis

Chai Hong Rim et al.

Summary: The concurrent application of sorafenib and external beam radiation therapy for advanced hepatocellular carcinoma may be a feasible option, especially for targeting metastatic lesions or vessel involvement. Clinical outcomes of concurrent treatment appear to be more beneficial than non-concurrent treatment, highlighting the importance of careful consideration when targeting intrahepatic lesions.

CANCERS (2021)

添加到收藏夹

Article Oncology

Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis

Chieh-Min Liu et al.

Summary: This study compared the effectiveness of radiotherapy alone versus concurrent radiotherapy and sorafenib for locally advanced hepatocellular carcinoma, showing no significant differences in overall survival and treatment-related toxicities between the two groups.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

添加到收藏夹

Letter Dermatology

Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies

A. Freites-Martinez et al.

ACTAS DERMO-SIFILIOGRAFICAS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

mRECIST for HCC: Performance and novel refinements

Josep M. Llovet et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases

Luca Nicosia et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial

Yue Hu et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Lenvatinib: A Review in Hepatocellular Carcinoma

Zaina T. Al-Salama et al.

DRUGS (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west

Jian Lu et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

Joong-Won Park et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

添加到收藏夹

Review Oncology

Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review

Chai Hong Rim et al.

RADIOTHERAPY AND ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Masahiro Matsuki et al.

CANCER MEDICINE (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies

Po-Hong Liu et al.

SEMINARS IN LIVER DISEASE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

Toshiyuki Tamai et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Oncology

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Masafumi Ikeda et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma

Shang-Wen Chen et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)

添加到收藏夹

Review Surgery

Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus

Satoshi Katagiri et al.

SURGERY TODAY (2014)

添加到收藏夹

Article Oncology

Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo

Wen Yu et al.

CANCER LETTERS (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma

Aaron T. Wild et al.

PLOS ONE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis

Mian Xi et al.

PLOS ONE (2013)

添加到收藏夹

Article Oncology

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner

Qiaoqiao Li et al.

BMC CANCER (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma

Giuseppe Cabibbo et al.

HEPATOLOGY (2010)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Stereotactic body radiation therapy: The report of AAPM Task Group 101

Stanley H. Benedict et al.

MEDICAL PHYSICS (2010)

添加到收藏夹

Review Gastroenterology & Hepatology

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

Riccardo Lencioni et al.

SEMINARS IN LIVER DISEASE (2010)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.